Europe Pharmaceutical Drug Delivery Market
Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe Pharmaceutical drug delivery market, valued at USD 519.6 million in 2026, is expected to expand to USD 703.2 million by 2031, reflecting a steady CAGR of 6.2% from 2025 to 2031. The Europe pharmaceutical drug delivery market is growing in response to a growing usage of biologics and biosimilars, a rising prevalence of chronic diseases, as well as an increasing acceptance of emerging drug delivery devices, including auto-injectors, prefilled syringes, and inhalation drug delivery devices. Furthermore, an aging population, growing usage of home care, and supportive regulatory policies that encourage patient-friendly drug delivery systems are also driving this market. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.
KEY TAKEAWAYS
-
By CountryGermany is projected to witness the highest growth rate of 7.2% during the forecast period in the Europe pharmaceutical drug delivery market.
-
By Route of AdministrationBy route of administration, the injectable drug delivery segment holds the largest share of 38.0% in 2025 in this market.
-
By ApplicationBy application, the autoimmune diseases segment is projected to experience the highest growth rate of 7.6% from 2026 to 2031.
-
By care settingBy care setting, the hospital segment holds the largest share of 58.8% in 2025 in the Europe pharmaceutical drug delivery market.
-
Competitive Landscape - Major PlayersGerresheimer AG (Germany) and Novo Nordisk (Denmark) stand out as star players in Europe because of their strong regional footprint, established product portfolios, and consistent leadership in advancing drug delivery technologies.
-
Competitive Landscape - StartupsCapa Valve Ltd (Belgium) and Pharma Latch (UK) are emerging players, gaining attention for their novel approaches to improving precision, ease of use, and patient experience in drug delivery.
In the EU, a growing interest in innovative drug delivery systems has been seen, as healthcare systems search for ways to improve drug delivery. Countries such as Germany, France, and the Nordic countries are driving this forward with their healthcare budgets. Meanwhile, new development policies and increasing sustainability needs are encouraging innovations in device development to create patient-centered and sustainable drug delivery systems in the future.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Some of emerging trends that are being noticed in Europe are the growing appeal of sustainable drug delivery packaging, using self-administration devices, and better integration of digital functionalities for compliance management. These emerging trends are influencing this market as companies are being compelled to innovate quickly, as a result of stricter government policies in the European Union.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising prevalence of chronic diseases

-
Increasing adoption of connected and self-administration devices
Level
-
Wide disparities in regulatory maturity and approval timelines
-
High-cost sensitivity in emerging markets
Level
-
Growing demand for wearable injectors, and home-care delivery solutions
-
Government investments in digital health
Level
-
High competition from low-cost local players
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising prevalence of chronic diseases
The rising incidence of chronic diseases like diabetes, cardiovascular diseases, respiratory diseases, and cancer in Europe has led to a growing demand for enhanced drug delivery devices. The increasing number of new cases of chronic diseases in Western and Northern Europe, along with their rising adoption of biologics in clinical practices, has further propelled the necessity for injectable, respiratory, long-acting, and self-administration devices. These factors are thus fueling the development of this market in the European Union.
Restraint: Wide disparities in regulatory maturity and approval timelines
The relatively structured but very different regulatory ecosystem in Europe brings certain differences in timelines for drug delivery devices and combination products among various member nations of the European Union. Although certain geographic areas such as Germany, Nordic nations, and France are streamlined in their review processes, certain other nations from Southern and Eastern Europe take a longer time for device evaluation, and compliance for device-related standards in those regions remains in a developing stage.
Opportunity: Growing demand for wearable injectors, and home-care delivery solutions
This trend is being driven by a shift towards decentralized care, integration with digital health, and self-administration solutions as health systems across the region look to reduce hospital burdens. The growing utilization of biologics, combined with supportive reimbursement pathways across major EU markets, along with increasing investments in connected drug delivery platforms, further solidifies this growth path. Furthermore, the expansion of home care adoption among ageing populations, accompanied by the EU's activities concerning harmonised device regulations, creates additional layers of potential for effective market expansion across the diverse European healthcare systems.
Challenge: High competition from low-cost local players
There is intense competition from low-cost regional sources that are a challenge in the European pharmaceutical drug delivery market, especially in commoditized product lines such as syringes, infusion sets, and other delivery kit components. This market faces a potential import challenge from Turkey, as well as a low-cost alternative from manufacturers in the Central and Eastern European countries. The primary drawback of this low-cost alternative market competition model is that it compromises innovation in niche technologies, thereby generating a limited return on investment for established market leaders.
europe-pharmaceutical-drug-delivery-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Builds a strong portfolio of injection-based delivery solutions, including smart pens, autoinjectors, and connected devices designed for diabetes, obesity management, and chronic care needs across Europe. | These intuitive delivery systems simplify self-treatment, support accurate dosing, and help improve day-to-day therapy adherence, aligning well with Europe’s growing shift toward home-based care. |
|
|
Offers a diverse set of delivery systems across oral, injectable, inhalation, and long-acting preparations, with particular emphasis on biologics, vaccines, and chronic therapeutic areas. | This breadth provides flexibility across disease areas, supports rapid deployment of new therapies, and ensures reliable drug performance for Europe’s varied healthcare environments. |
|
|
Specializes in precision-engineered primary packaging and drug delivery components, including prefillable syringes, inhalation parts, and device-integrated solutions tailored for European regulatory and manufacturing needs. | High-performance components elevate dosing reliability, enhance safety standards, and enable seamless integration into pharma partners’ combination products, reinforcing Gerresheimer’s role as a key enabler for EU biologics and injectables. |
|
|
Strengthens its delivery landscape through advanced inhalation technologies, subcutaneous biologic platforms, and targeted delivery systems for next-generation therapies. | These innovations support more convenient treatment pathways, improve patient comfort, and demonstrate strong leadership in designing delivery systems suited for complex, evolving therapeutics. |
|
|
Advances a wide mix of delivery formats—from oral and injectable options to lipid nanoparticle and mRNA-based systems—supported by deep formulation and controlled-release capabilities. | This broad delivery toolbox allows Pfizer to support innovative biologics and vaccines while ensuring consistent, efficient drug administration for large patient populations across Europe. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The strong network of device manufacturers, global and regional pharma companies, and advanced healthcare institutions propels the adoption of innovative delivery systems, shaping the Europe pharmaceutical drug delivery ecosystem. This is supported by a well-defined regulatory framework led by EMA, MHRA, and national authorities to make sure that the standards for safety, combination-product evaluation, and market access are very high. All these put together create a mature, innovation-driven market with consistent demand for advanced injectable, inhalation, and transdermal delivery technologies.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
By Application
The autoimmune diseases segment is one of the fastest-growing segments in applications within the EU during the period of 2026–2031, driven by the increasing cases of rheumatoid arthritis, psoriasis, and inflammatory bowel disease. With a greater pool of biologic and targeted therapies hitting the market-many with injectable or infusion-based mechanisms of delivery-demand for advanced systems also remains on the increase. Better diagnosis and wider access to treatments, along with a trend toward self-injectable options in therapies, add to the higher demand for specialized drug delivery solutions in the care of autoimmune diseases
By Care Setting
By care setting, hospitals are anticipated to register the largest share in 2025 due to their high volume of acute care, infusion, and complex biologics that require monitoring. Hospitals in Europe benefit from a superior purchasing position in their markets and a preference for adopting advanced infusion pumps, injectable, and controlled delivery systems early. Increasing surgical volumes, cancer cases, and emergency care also solidify that drug delivery remains, for now, in a hospital setting, despite the development of home healthcare options
By Route of Administration
Based on the route of administration, injectables are projected to lead in 2025 as a result of rising European reliance on biologics and biosimilars for cancer, autoimmune, and chronic diseases. These prefilled injectables in syringe, auto-injector, or pen form continue to be in vogue due to their ease of use, precision, and portability. Moreover, increasing acceptance of patient self-administration, coupled with support for combination product development, further validates injectables as the most popular administration routes in Europe
REGION
By Region
Germany is also likely to experience the fastest growth rate, with a well-functioning healthcare infrastructure, a high proportion of biologic prescriptions, and a rapid adoption rate of user-controlled devices such as auto-injectors and prefilled syringes. The country has a sizable number of seniors, an extensive hospital network, and favourable government policies that encourage the usage of superior delivery systems. In addition to that, Germany’s long-standing strength in R&D and manufacturing in the pharmaceutical domain keeps promoting injectable, inhalation, and wearable delivery systems for various therapy classes.

europe-pharmaceutical-drug-delivery-market: COMPANY EVALUATION MATRIX
The strong network of device manufacturers, global and regional pharma companies, and advanced healthcare institutions propels the adoption of innovative delivery systems, shaping the European pharmaceutical drug delivery ecosystem. This is supported by a well-defined regulatory framework led by EMA, MHRA, and national authorities to make sure that the standards for safety, combination-product evaluation, and market access are very high. All these put together create a mature, innovation-driven market with consistent demand for advanced injectable, inhalation, and transdermal delivery technologies.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Johnson & Johnson Services, Inc. (US)
- Pfizer Inc. (US)
- Fresenius Kabi (Germany)
- Becton, Dickinson and Company (US)
- Nemera (France)
- B. Braun (Germany)
- Gerresheimer AG (Germany)
- SHL Medical (Switzerland)
- Novo Nordisk (Denmark)
- Novartis (Switzerland)
- Sanofi (France)
- Baxter International (US)
- AstraZeneca (UK)
- Roche (Switzerland)
- medmix (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 501.6 MN |
| Market Size in 2031 (Value) | USD 703.2 MN |
| CAGR | 6.2% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD MN), Volume (Thousands Unit) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regional Scope | Germany, France, Italy, UK, Spain and Rest of Europe |
WHAT IS IN IT FOR YOU: europe-pharmaceutical-drug-delivery-market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Assessed key drug-delivery types in Europe—oral, injectable, inhalation, transdermal, implantable, nanoparticle-based, and connected devices. Evaluated performance, regulatory expectations, and innovation trends used by leading manufacturers. | Helped clients select suitable delivery technologies, compare long-acting and device–drug options, and understand emerging platforms such as mRNA systems and smart injectors. Supported product planning for chronic disease and biologics-focused treatments. |
| Company Information | Profiled major global and Europe drug-delivery players, covering portfolios, platforms, partnerships, manufacturing, and R&D efforts. Analyzed strengths in biologic and sustained-release delivery. | Enabled clients to gauge competitor capabilities, assess supplier fit for injectables and device partners, and identify collaboration or outsourcing opportunities. Strengthened long-term strategy in biologics and advanced delivery solutions. |
| Geographic Analysis | Examined Europe delivery trends across regulatory systems, biologics expansion, home-care adoption, and manufacturing hubs. Included reimbursement and digital-health ecosystem insights, with optional country-level customization. | Supported strategic market entry by identifying growth areas, localization options, and supply-chain opportunities. Helped clients evaluate patient preferences and emerging demand in home-based and biologics-driven delivery segments across diverse Europe markets. |
RECENT DEVELOPMENTS
- May 2024 : Novartis took a step to expand its cancer care portfolio through the acquisition of Mariana Oncology which in turn gives the company access to next generation radioligand therapies for the most challenging oncology issues
- July 2023 : GSK added to its respiratory pipeline via the purchase of Bellus Health which brought in camlipixant, a late stage P2X3 antagonist for refractory chronic cough
- June 2023 : Merck expanded into the immunology and gastroenterology fields via the acquisition of Prometheus which brought to the company innovative products for the treatment of ulcerative colitis, Crohn’s disease and other auto immune issues
- June 2023 : Merck expanded its immunology and gastroenterology pipeline via the acquisition of Prometheus which brought in to the company innovative candidates for ulcerative colitis, Crohn’s disease and other auto immune conditions
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
- 5.1 PORTER’S FIVE FORCES ANALYSIS
-
5.2 MACROECONOMICS OUTLOOKINTRODUCTIONGDP TRENDS AND FORECASTTRENDS IN GLOBAL HEALTHCARE INDUSTRYTRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
-
5.6 PRICING ANALYSISAVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CARE SETTING, 2025AVERAGE SELLING PRICE TREND, BY ROUTE OF ADMINISTRATION, 2023-2025AVERAGE SELLING PRICE TREND, BY COUNTRY, 2023-2025AVERAGE SELLING PRICE TREND, BY APPLICATION, 2023-2025
-
5.7 TRADE ANALYSISIMPORT SCENARIO (HS CODE 901831)EXPORT SCENARIO (HS CODE 901831)
- 5.8 KEY CONFERENCES AND EVENTS, 2026–2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
- 5.10 INVESTMENT AND FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS/SUCCESS STORIES AND REAL-WORLD APPLICATIONS
-
5.12 IMPACT OF 2025 US TARIFF ON EUROPE PHARMACEUTICAL DRUG DELIVERY MARKETINTRODUCTIONKEY TARIFF RATESPRICE IMPACT ANALYSISIMPACT ON COUNTRYIMPACT ON END-USE INDUSTRIES
-
6.1 KEY EMERGING TECHNOLOGIESSMART & CONNECTED DRUG DELIVERY SYSTEMSNANOTECHNOLOGY-BASED DRUG DELIVERY
-
6.2 COMPLEMENTARY TECHNOLOGIES3D-PRINTED AND PERSONALIZED DRUG DELIVERY SYSTEMSSMART CONNECTED INHALATION SYSTEMS
-
6.3 ADJACENT TECHNOLOGIESSMART MONITORING, IOT & DATA-DRIVEN CONTROLNEXT-GENERATION FILTRATION & CONTAMINATION CONTROL
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.6 FUTURE APPLICATIONS
-
6.7 IMPACT OF AI/GEN AI ON EUROPE PHARMACEUTICAL DRUG DELIVERY MARKETTOP USE CASES AND MARKET POTENTIALBEST PRACTICES IN EUROPE PHARMACEUTICAL DRUG DELIVERYCASE STUDIES OF AI IMPLEMENTATION IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKETINTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERSCLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
-
7.1 REGIONAL REGULATIONS AND COMPLIANCEREGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONSINDUSTRY STANDARDS
- 7.2 REGIONAL REIMBURSEMENT ANALYSIS
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
- 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
- 8.5 MARKET PROFITIBILITY
- 9.1 INTRODUCTION
-
9.2 INJECTABLE DRUG DELIVERYCONVENTIONAL INJECTION DEVICES- BY MATERIAL- BY RODUCT- BY USABILITYSELF-INJECTION DEVICES- NEEDLE-FREE INJECTORS- AUTOINJECTORS- PEN INJECTORS- WEARABLE INJECTORS
-
9.3 ORAL DRUG DELIVERYSOLID ORAL DRUGS- TABLETS- CAPSULES- ORAL POWDERS- PILLSLIQUID ORAL DRUGS- ORAL SYRUPS- ORAL SOLUTIONS- ORAL EMULSIONS- ORAL ELIXIRSSEMI-SOLID ORAL DRUGS- ORAL GELS- ORAL PASTES
-
9.4 TOPICAL DRUG DELIVERYLIQUID TOPICAL DRUG FORMULATIONS- TOPICAL SOLUTIONS- TOPICAL EMULSIONS- TOPICAL SUSPENSIONSSOLID TOPICAL DRUG FORMULATIONS- SUPPOSITORIES- POWDERSSEMI-SOLID TOPICAL DRUG FORMULATIONS- CREAMS- GELS- OINTMENTS- PASTES- LOTIONSTRANSDERMAL DRUG FORMULATIONS- TRANSDERMAL PATCHES- TRANSDERMAL GELS- TRANSDERMAL SPRAYS
-
9.5 OCULAR DRUG DELIVERYLIQUID FORMULATIONS- EYE DROPS- LIQUID OCUALR SPRAYSSEMI-SOLID FORMULATIONS- OCUALR GELS- EYE OINTMENTSOCULAR DEVICES- DRUG COATED CONTACT LENSES- OCULAR INSERTS
-
9.6 PULMONARY DRUG DELIVERYMETHOD DOSE INHALERSDRY POWDER INHALERSNEBULIZERS- JET NEBULIZERS- ULTRASONIC NEBULIZERS- SOFT MIST NEBULIZERS
-
9.7 NASAL DRUG DELIVERYNASAL DROPSNASAL SPRAYSNASAL POWDERSNASAL GELS
-
9.8 TRANSMUCOSAL DRUG DELIVERYORAL TRANSMUCOSAL FORMULATIONS- BUCCAL DRUG DELIVERY- SUBLINGUAL DRUG DELIVERYOTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES- RECTAL TRANSMUCOSAL DRUG DELIVERY- VAGINAL TRANSMUCOSAL DRUG DELIVERY
-
9.9 IMPLANTABLE DRUG DELIVERYACTIVE IMPLANTABLE DRUG DELIVERYPASSIVE IMPLANTABLE DRUG DELIVERY
- 10.1 INTRODUCTTION
- 10.2 INFECTIOUS DISEASES
- 10.3 CANCER
- 10.4 CARDIOVASCULAR DISEASES
- 10.5 DIABETES
- 10.6 RESPIRATORY DISEASES
- 10.7 AUTOIMMUNE DISEASES
- 10.8 CENTRAL NERVOUS SYSTEM DISORDERS
- 10.9 OTHER APPLICATIONS
- 11.1 INTRODUCTION
- 11.2 HOSPITALS
- 11.3 AMBULATORY SURGICAL CENTERS/CLINICS
- 11.4 HOME CARE SETTINGS
- 11.5 DIAGNOSTIC CENTERS
- 11.6 OTHER CARE SETTINGS
- 12.1 INTRODUCTION
-
12.2 EUROPEGERMANYFRANCEITALYUKSPAINREST OF EUROPE
- 13.1 OVERVIEW
- 13.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
- 13.3 REVENUE ANALYSIS, 2023-2025
- 13.4 MARKET SHARE ANALYSIS, 2025
- 13.5 BRAND/PRODUCT COMPARISON
-
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025STARSEMERGING LEADERSPERVASIVE PLAYERSPARTICIPANTSCOMPANY FOOTPRINT: KEY PLAYERS, 2025- COMPANY FOOTPRINT- ROUTE OF ADMINISTRATION FOOTPRINT- APPLICATION FOOTPRINT
-
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025PROGRESSIVE COMPANIESRESPONSIVE COMPANIESDYNAMIC COMPANIESSTARTING BLOCKSCOMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025- DETAILED LIST OF KEY STARTUPS/SMES- COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
- 13.8 COMPANY VALUATION & FINANCIAL MATRICS
-
13.9 COMPETITIVE SITUATION AND TRENDSPRODUCT LAUNCHESDEALSEXPANSIONSOTHER DEVELOPMENTS
-
14.1 KEY PLAYERSJOHNSON & JOHNSON SERVICES, INC.PFIZER INC.FRESENIUS KABIBECTON, DICKINSON AND COMPANYNEMERAB. BRAUNGERRESHEIMER AGSHL MEDICALNOVO NORDISKNOVARTISSANOFIBAXTER INTERNATIONALASTRAZENECAROCHEMEDMIX
-
14.2 OTHER PLAYERSCAPA VALVE LTD.PHARMA LATCHECO-INJECTONDOSIS ABWINDGAP MEDICAL, INC.
-
15.1 RESEARCH DATASECONDARY DATA- KEY DATA FROM SECONDARY SOURCESPRIMARY DATA- KEY DATA FROM PRIMARY SOURCES- KEY PRIMARY PARTICIPANTS- BREAKDOWN OF PRIMARY INTERVIEWS- KEY INDUSTRY INSIGHTS
-
15.2 MARKET SIZE ESTIMATIONBOTTOM-UP APPROACHTOP-DOWN APPROACHBASE NUMBER CALCULATION
-
15.3 MARKET FORECAST APPROACHSUPPLY SIDEDEMAND SIDE
- 15.4 DATA TRIANGULATION
- 15.5 FACTOR ANALYSIS
- 15.6 STUDY ASSUMPTIONS
- 15.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
- 16.1 INSIGHTS OF INDUSTRY EXPERTS
- 16.2 DISCUSSION GUIDE
- 16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
-
16.4 CUSTOMIZATION OPTIONSGEOGRAPHIC ANALYSISCOUNTRY-LEVEL MARKET SHARE ANALYSISCOMPANY INFORMATIONPRODUCT ANALYSISCOUNTRY-LEVEL VOLUME ANALYSISANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTBY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
- 16.5 RELATED REPORTS
- 16.6 AUTHOR DETAILS
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), American Journal of Drug Delivery and Therapeutics, Center for Drug Delivery and Nanomedicine (CDDN) and Parenteral Drug Association (PDA) were referred to identify and collect information for the global Europe Pharmaceutical Drug Delivery Market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the Europe Pharmaceutical Drug Delivery Market. The primary sources from the demand side include hospitals, ambulatory surgical centers/clinics, home care setting, diagnostic centers among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
Market Estimation Methodology
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global Europe Pharmaceutical Drug Delivery Market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 45-48% of the market share at the global level). Also, the global Europe Pharmaceutical Drug Delivery Market was split into various segments and sub-segments based on:
- List of major players operating in the pharmaceutical drug delivery products market at the regional and/or country level
- Product mapping of various pharmaceutical drug delivery manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from pharmaceutical drug delivery (or the nearest reported business unit/product category)
- Revenue mapping of major players to cover at least 45% of the global market share as of 2023
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global point-of-care diagnostics market
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Data Triangulation
After arriving at the overall size of the global Europe Pharmaceutical Drug Delivery Market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Market Definition
Drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.
Key Market Stakeholders
- Pharmaceutical manufacturing companies
- Original equipment manufacturing companies
- Suppliers and distributors of pharmaceutical products and medical devices
- Healthcare service providers
- Teaching hospitals and academic medical centers
- Health insurance players
- Government bodies/municipal corporations
- Regulatory bodies
- Medical research institutes
- Business research and consulting service providers
- Venture capitalists
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the global Europe Pharmaceutical Drug Delivery Market on the basis of pharmaceutical drug delivery product, route of administration, application, facility of use, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global Europe Pharmaceutical Drug Delivery Market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global Europe Pharmaceutical Drug Delivery Market report.
Product Analysis
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.
Company Information
- Detailed analysis and profiling of additional market players (up to 5 players)
Geographic Analysis
- Further breakdown of the Rest of Europe Europe Pharmaceutical Drug Delivery Market into Belgium, Austria, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
- Further breakdown of the Rest of Asia Pacific Europe Pharmaceutical Drug Delivery Market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
- Further breakdown of the Rest of Latin America Europe Pharmaceutical Drug Delivery Market into Argentina, and Colombia, among other countries.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Pharmaceutical Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Pharmaceutical Drug Delivery Market